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Abstract:  30 
Classically, Eosinophilic Esophagitis is an antigen mediated chronic disease 31 
distinct from gastroesophageal reflux disease. Eosinophilic Esophagitis is an 32 
emerging clinical problem that is growing in recognition. It is characterized clinically 33 
by feeding dysfunction, dysphagia and reflux-like symptoms. Histologically, 34 
Eosinophilic Esophagitis is identifiable by a dense epithelial eosinophilic infiltrate. 35 
Experimental modeling and clinical studies over the last decade have greatly 36 
improved mechanistic insights and led to improvements in clinical understanding and 37 
the assessment of therapeutic options for patients and their clinicians who manage 38 
this disease. Here, we review the clinicopathologic diagnostic criteria and our 39 
understanding of Eosinophilic Esophagitis as an allergic disease with genetic and 40 
immunological components. We present studies defining the importance of the 41 
epithelial barrier and the concept of barrier dysfunction as an initiating or perpetuating 42 
factor for this disease. We discuss the relationship between the symptoms of 43 
dysphagia and feeding dysfunction, our current knowledge of the underlying 44 
pathophysiologic mechanisms, and advances in clinical assessment of esophageal 45 
distensibility and narrowing in Eosinophilic Esophagitis patients. Lastly, therapeutic 46 
implications relating to the advances that have led to our current understanding of the 47 
pathophysiology of Eosinophilic Esophagitis are explored.   48 
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Introduction 49 
In its healthy state, the esophagus provides for safe passage of nutrition from 50 
the mouth to the stomach. This remarkable feat is accomplished by complex innate 51 
features of defense that include mucus, bicarbonate, defensins, squamous epithelial 52 
cells, and a network of neurons and smooth muscle cells that are arranged in 53 
longitudinal and circular fashion. Close inspection of the epithelium reveals an 54 
intricate array of stratified epithelia that are closely connected by a series of junctional 55 
molecules and interspersed with a number of lymphocytes and other leukocytes such 56 
as mast cells. In contrast to the rest of the healthy gastrointestinal (GI) tract where 57 
eosinophils are present, eosinophils are absent in the normal esophageal mucosa.  58 
To provide a deep understanding of the clinical features and pathophysiologic 59 
mechanisms underlying eosinophilic esophagitis (EoE), it is important to provide 60 
historical context of this relatively new disease. Prior to 1960, interrogations of the 61 
intestinal mucosa were limited to surgical resections or post mortem analyses. The 62 
advent of luminal fiberoptic endoscopy in the 1960’s, afforded a new opportunity to 63 
develop detailed histologic examination of the GI mucosa. In the 1980’s, endoscopic 64 
procedures were performed on adults and an increasing number of pediatric patients 65 
who had gastroesophageal reflux (GERD) like symptoms. Analysis of mucosal 66 
biopsies revealed a pattern of scattered epithelial eosinophilia (82). Soon thereafter, 67 
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some patients with reflux and other symptoms recalcitrant to acid blockade 68 
were found to have a pattern different from that previously associated with 69 
GERD, one that revealed dense mucosal eosinophilia of greater than 15 70 
eosinophils per high power field (4, 33, 75). Clinically, these patients presented 71 
uniquely from GERD and instead of a history of heartburn or regurgitation, 72 
adult patients noted problems with solid food dysphagia and food impaction. In 73 
contrast, children with EoE were found to have profound feeding difficulties 74 
and in some circumstances, failure to thrive.  75 
Over the course of the last 20 years, a clinical and molecular profile emerged 76 
that distinguishes EoE from its counterpart, GERD (57). Conceptually, a paradigm 77 
has arisen that may help to distinguish between these two esophageal 78 
diseases. GERD is understood to be a disorder of motility and if complications 79 
arise, they likely occur as a result of chronic mucosal inflammation (24, 76). 80 
GERD related inflammation could be considered an “outside-in” process in 81 
which luminal gastric refluxate initiates and perpetuates epithelial inflammation 82 
resulting in an endoscopic appearance of friability and histologically in the 83 
disruption of mucosal integrity. In contrast, EoE is conceptually considered, a 84 
chronic, allergic inflammatory disorder with symptoms and complications that 85 
are related to destructive tissue remodeling. In this paradigm, of an “inside-out” 86 
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disease, allergic inflammation can arise in a genetically predisposed patient in 87 
whom chronic antigenic stimulation leads to a type-2 inflammatory response 88 
that in some case results in excessive mucosal and submucosal tissue 89 
remodeling (57). In contrast to GERD, the endoscopic appearance of EoE is 90 
characterized by surface exudate (white plaques), thickened mucosa (linear 91 
furrows and edema) and chronic remodeling (rings and strictures) as well as a 92 
rubbery texture. In reality, there is likely an overlap between GERD and EoE and 93 
the relationship between clinical features and pathophysiological mechanisms 94 
continues to be defined(22). 95 
 96 
Clinical features and diagnosis of EoE 97 
EoE is diagnosed in patients who have symptoms of esophageal dysfunction with 98 
dense esophageal eosinophilia in whom other causes have been ruled out (38). The 99 
increasing incidence of EoE in pediatric and adult populations was last estimated at 1 100 
in 10,000 (19). Patients can be affected at any age. EoE is more common in 101 
Caucasians and has a clear male predominance (male: female ratio is about 3:1). In 102 
addition, EoE accounts for 5-16% of patients with dysphagia, and approximately half 103 
of patients with food impaction (20). Approximately 30-60% of patients have 104 
comorbidity for one or more classical allergic disorders, such as bronchial asthma 105 
Downloaded from www.physiology.org/journal/ajpgi by ${individualUser.givenNames} ${individualUser.surname} (140.226.006.023) on September 18, 2018.
Copyright © 2018 American Physiological Society. All rights reserved.
and food allergy (59). EoE related symptoms differ between young patients (infants 106 
and children) and adults (38). Infants and children often exhibit a wide range of 107 
nonspecific symptoms such as feeding difficulty, reflux and vomiting. Thus, 108 
clinical recognition of EoE in children may be more difficult than in adults. 109 
Teenagers and adults, develop stereotypical patterns of solid food dysphagia, 110 
food impaction and chest pain. On the other hand, symptoms resembling 111 
GERD, such as heartburn and precordial pain, are common regardless of age. 112 
Symptoms may be underestimated by the patient's adaptation (long mealtimes, 113 
preference for minced foods, frequent drinking during meals)(52). It is unclear 114 
whether these symptomatic differences reflect the ability to report symptoms, 115 
duration of illness or different pathophysiology of disease (68).  116 
 In order to properly diagnose EoE, various diseases such as GERD, 117 
esophageal cancer, achalasia, hypereosinophilic syndrome, infection, Crohn's 118 
disease, and drug allergies need to be ruled out. Of these, the major challenge 119 
lies in differentiation from GERD and addressing the previous diagnostic 120 
guidelines requiring empirical treatment of high dose proton pump inhibition 121 
(38). Since the original diagnostic consensus recommendations were 122 
published, it has become clear that proton pump inhibitors (PPIs) exert a 123 
significant impact in reducing symptoms and esophageal eosinophilia in 124 
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patients. Such patients have been termed to have PPI-Responsive Esophageal 125 
Eosinophilia (PPI-REE). The last decade’s worth of clinical experiences and 126 
research showed that many of these patients exhibit no obvious differences in 127 
clinical or molecular profiles when compared to those who have classical EoE 128 
(47). Therefore, patients described as having PPI-REE may actually represent a 129 
subset of patients with EoE who respond to PPIs. Thus, the trial of PPI has 130 
been excluded from diagnostic recommendations (22, 39). The implications of 131 
this change are significant and include decreased exposure to PPIs, reduction 132 
in time to diagnosis, fewer endoscopies to establish diagnosis and a deeper 133 
understanding of treatment naïve esophageal mucosa. 134 
 135 
Allergies and genetic impact on EoE phenotypes 136 
In 1996, Kelly et al. reported the first series of children with EoE and made the 137 
seminal observation that symptoms and histopathology responded to an amino acid 138 
based diet and upon food reintroduction, symptoms and epithelial eosinophilia 139 
returned (33). This finding provided the first evidence that esophageal eosinophilia 140 
may have an underlying allergic etiology. Since then, a number of prospective trials of 141 
food elimination documented the ability of dietary restriction to induce histologic 142 
remission of EoE in upwards of 43% - 74% of children and adults (49). Peripheral 143 
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eosinophilia is found in 40-50% of patients (38). In addition, a number of clinical 144 
studies further characterized the allergic phenotype of patients with EoE 145 
identifying that between 28-86% of adults, and between 42-96% of pediatric 146 
patients may be affected by one or more co-morbid allergic diseases such as 147 
atopic dermatitis, food allergies, asthma or allergic rhinitis (38).  148 
Studies examining the molecular underpinnings of EoE focus on 149 
chemokine’s known to be related to eosinophilia (e.g. eotaxin-3) and type 2 150 
cytokines (e.g. IL-5 and IL-13). Microarray analysis using esophageal specimens 151 
reveal that eotaxin-3 has the largest fold change in mRNA expression level between 152 
EoE patients and controls. In addition, eotaxin-3 expression in tissues strongly 153 
correlates with tissue eosinophil and mast cell counts (9). IL-5 participates in 154 
eosinophil maturation and eventual migration into the esophageal epithelium and IL-5 155 
mRNA and protein is increased in the esophagus of EoE patients(73). Subsequent 156 
studies examined the role of IL-5 in murine models of EoE demonstrating a key role 157 
for IL-5 in esophageal eosinophilia (45). Similarly, IL-13 is increased in tissue sections 158 
of EoE patients and stimulation of esophageal epithelia with IL-13 leads to the 159 
production of eotaxin-3, a major eosinophil chemotactic factor as well as diminished 160 
expression of filaggrin and results in decreased esophageal barrier function (6, 8). 161 
Using a translational approach, Cianferoni et al. found that Th2 cells expressing IL-4, 162 
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IL-5 and IL-13 significantly increased in peripheral blood in the active phase of EoE 163 
patients who did not have milk-specific IgE (15), further implicating type 2 164 
immunity as a target for treatments in EoE. Several therapeutic trials have 165 
targeted type 2 cytokines in EoE to limited success. Trials using anti-IL-5 and 166 
anti-IL-13 antibodies both document their ability to diminish esophageal 167 
eosinophilia. Despite these impressive findings, these studies did not support 168 
clinical use because they were unable to meet the endpoint of symptom reduction (29, 169 
61, 71, 74). Clinical trials of anti-IL-4Rα (dupilumab) are in progress (NCT02379052). 170 
 In order to provide a unbiased approach, a genome wide association studies  171 
(GWAS) provided further support for an underlying allergic/Th2 cytokine mechanism 172 
for EoE (66, 70) In these studies, single nucleotide polymorphisms (SNP) in the 173 
TSLP locus were identified in EoE subjects but not controls. TSLP expression is 174 
increased in esophageal tissues of EoE patients. TSLP acts on dendritic cells evoking 175 
a Th2 dominant immune response. Artis et al provide confirmation of a role for TSLP 176 
in the underlying pathogenesis of esophageal eosinophilia (55). In this study, 177 
inhibition of TSLP led to the reduction food impactions and eosinophilia in an EoE 178 
mouse model.  179 
 An emerging body of evidence supports the association of 180 
immunoglobulin patterns in EoE. For instance, IgG4 is increased in EoE tissues 181 
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(16, 65). Despite earlier hope that IgE mediated mechanisms may provide diagnostic, 182 
therapeutic and pathogenetic insights for EoE patients, a growing body of evidence 183 
does not support its direct role. Mouse models of EoE demonstrate the ability of B 184 
cell-deficient mice to develop esophageal eosinophilia(46). IgE is not elevated in all 185 
EoE patients and when increased, it is difficult to ascertain whether it is due to EoE or 186 
other underlying allergic conditions. Omalizumab, an anti-IgE monoclonal antibody, 187 
was not effective in inducing remission of EoE(16).  188 
 The impact of epigenetics and environmental factors on EoE continues to 189 
emerge. Caesarian section, preterm birth, exposure to antibiotics in infantile period, 190 
reduced breast feeding, and living in less crowded area have all been linked to an 191 
increase of EoE (30, 31). As with the increase in other allergic diseases, the “Hygiene 192 
Hypothesis” may also help to explain the recent increase in EoE. Decreased 193 
exposure to bacteria within 2 to 3 years after birth can evoke Th2-dominant 194 
immunological status, and thus a propensity to develop allergic disease (31, 77). 195 
Based on similarity to the other classical allergic disorders, such deviation of Th1/Th2 196 
balance stemming from the change in lifestyle could relate to the increase in EoE. For 197 
example decreased bacterial exposure in infancy and childhood may relate to the 198 
decreased rate of Helicobacter pylori detection in the general population (44). Such 199 
decreases are especially prominent in developed countries, where the incidence of 200 
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EoE appears to be high. At least one study demonstrates that the infection rate of 201 
Helicobacter pylori is inversely correlated to esophageal eosinophilia, but it is unclear 202 
whether there is direct causative relationship or not (23). A recent study did not find 203 
this same association indicating the need for more epidemiologic and mechanistic 204 
studies (48). 205 
 206 
Barrier dysfunction; the chicken or the egg of the EoE story? 207 
A number of hypotheses have been raised regarding diminished esophageal 208 
barrier function in EoE. First, some patients with EoE may have diminished epithelial 209 
barrier at baseline when not inflamed thus predisposing them to allergic sensitization 210 
or challenge; this model is similar to that seen in atopic dermatitis. Indeed, 211 
transcriptional alterations have been found in human chromosome 1q21, which 212 
encodes for a group of genes related to epidermal differentiation including filaggrin (8) 213 
and another tissue specific proteolytic molecule, calpain14 (35). Altered expression of 214 
these genes may predispose to barrier dysfunction at baseline or after activation by 215 
Type 2 cytokines such as IL-13 (8). A recent translational study measured the 216 
esophageal barrier using impedance monitors in adult EoE patients before and 217 
after treatment (80). They determined that following treatment, esophageal barrier 218 
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was still reduced compared to normal values indicating a potential innate barrier 219 
defect. 220 
Second, the impaired barrier may develop as a result of peptic or other injury. 221 
This hypothesis, termed the “two-hit hypothesis”, is based on the clinical observation 222 
that EoE may develop after an epithelial insult from acid injury, trauma or infection (13, 223 
27). In this circumstance, food or aeroallergens may then contact the damaged 224 
epithelium and sensitized microenvironment in the esophageal mucosa leading to 225 
activation of a type 2 inflammatory pathway. 226 
Finally, barrier dysfunction may occur as a self-perpetuating product of 227 
ongoing inflammation. In this circumstance, once an inflammatory process starts, the 228 
epithelial surface may become increasingly permissive and allow more allergenic 229 
stimulation to penetrate and develop an ongoing allergic cycle. Support for this 230 
paradigm is based on histological findings of actively inflamed tissues that 231 
demonstrate dilated intercellular spaces (Figure 2) and decreased desmosomes, as 232 
well as abnormal impedance measurements in inflamed tissue compared to normal 233 
(10, 79). 234 
All of these hypotheses may help to explain part of the barriers’ role in EoE, 235 
and several lines of evidence dissect the underlying associated pathways using 236 
various model systems. Translational studies utilizing impedance monitors and 237 
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Ussing chamber studies reveal that the barrier is leaky during active inflammation 238 
compared to inactive disease (80). Gene arrays laid the basis of several mechanistic 239 
studies demonstrating the importance of IL-13 in barrier dysfunction. IL-13 240 
downregulates filaggrin and desmoglein-1 and upregulates calpain 14, all of which 241 
can contribute to diminished barrier. Filaggrin deficiency is also noted in patients with 242 
atopic dermatitis (58), another allergic disease associated with dysfunctional barrier. 243 
Genetic silencing of desmoglein induced barrier disruption in vitro (67). GWAS 244 
studies highlighted increased CAPN14 expression associated with a subpopulation of 245 
EoE (35), while in vitro culture of esophageal epithelial cells with IL-13 led to 246 
increased CAPN14 expression and a subsequent loss of barrier function implicating 247 
its importance in barrier dysfunction in EoE (18). In addition to its role in 248 
remodeling, TGF-β1 also decreased epithelial barrier function in vitro, by mediating a 249 
decrease in the expression of the tight junction molecule Claudin 7 (53). Taken 250 
together, the role of an intact barrier is likely critical to disease processes in EoE. 251 
 252 
Relationship of dysphagia and feeding problems with esophageal remodeling 253 
in EoE 254 
Dysphagia, in adults, and feeding problems, in children, are some of the most 255 
common presenting symptoms of EoE (52) that may relate to dysmotility or excessive 256 
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remodeling. Both of these symptoms pose significant challenges for the evaluation 257 
and treatment of EoE patients. Patients often develop coping mechanisms to limit 258 
symptoms. Instead of reporting difficulty swallowing, they may self-limit themselves 259 
from eating highly textured foods that are difficult to swallow such as bread, steak or 260 
rice. Parents may report excessively prolonged mealtimes due to drinking copious 261 
amounts of water or chewing food excessively, often to the point of pulverization. 262 
These symptoms pose the practical problem related to caring for a child who 263 
may take hours to feed a meal or limiting social exposure because of 264 
embarrassment. They also create a barrier to completing therapeutic studies in 265 
which this type of symptom has been difficult to measure. Over the last few 266 
years, symptom assessments for adults with EoE have been developed that take this 267 
symptom into account (63). Other metrics to assess disease status which incorporate 268 
the remodeling that occurs with chronic inflammation include barium esophagrams 269 
with pill (43), endoscopic scoring of the mucosal surface (81), histological 270 
assessments (17) and most recently catheter based measurement of esophageal 271 
distensibility (42). 272 
 The underlying pathogenetic mechanisms that explain these symptoms are 273 
not yet certain but early clinical studies suggested these problems might result from 274 
overabundant remodeling of the epithelium, lamina propria, vasculature and the 275 
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deeper esophageal wall, or to disordered motility (26, 56). Remodeling in itself is a 276 
necessary and critical part of host defense, but in excess can result in pathological 277 
outcomes. For instance, the esophageal lumen in some patients with EoE is partially 278 
occluded due to either isolated, focal or diffuse, longitudinal stricture formation. 279 
The classical histological findings of EoE include esophageal eosinophilia and 280 
rete peg elongation. Additionally, evidence of dense collagen fibrils in the 281 
lamina propria may represent problematic scarring. A number of molecules 282 
have been implicated as targets of esophageal remodeling including mediators 283 
such as TGF-β1, CCL-18, and FGF-9.  Fibroblast activation occurs in response to 284 
TGF-β1 in vitro leading to the secretion of fibrotic factors such as collagen and 285 
fibronectin (50, 60). Epithelial and sub-epithelial fibrosis has also been noted in EoE 286 
(12), with epithelial cells themselves contributing to remodeling through mechanisms 287 
such as epithelial-mesenchymal like transitions in response to factors including 288 
TGF-β1 (32, 50, 51).  Increased vascular density and expression of activation 289 
markers has been noted in EoE patients (2), while pre-clinical models treated with 290 
anti-eosinophil (62) and anti-GM-CSF (41) reveal reduced vascular remodeling, 291 
implicating remodeled vasculature as a response to chronic inflammation in EoE. 292 
Cytokine involvement in the pathophysiology of EoE is also supported by the effects 293 
of cytokine targeted drugs (anti-IL-5, anti-IL-13) on epithelial eosinophil 294 
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chemoattractant CCL26 production and subsequent esophageal eosinophilic 295 
infiltration (3, 7, 14, 45, 61, 74) Finally, exposure of esophageal smooth muscle cells 296 
to TGF-β1 leads to smooth muscle cell activation in vitro, resulting in increased 297 
contraction (1, 5, 60).   298 
New technology has brought more understanding of the functional 299 
aspects of this esophageal remodeling. Functional Luminal Imaging Probe (FLIP) 300 
is a catheter-based technology that upon volume-based insufflation permits 301 
measurement of esophageal compliance. Results from studies using this device in 302 
adults demonstrate decreased distensibility in patients with EoE compared to controls 303 
(37, 54). In children with EoE, distensibility was decreased compared to normal 304 
controls and improved following treatment (42). Moreover, longitudinal studies have 305 
demonstrated that treatment with either steroids or diet elimination improves 306 
distensibility. These studies also demonstrated that improved distensibility correlated 307 
with patient reported symptom severity indices possibly more so than the traditional 308 
marker of histological marker of disease severity, eosinophils/hpf (11). Evaluations of 309 
distensibility potentially offer a predictive quality as shown in an adult study in which, 310 
a threshold distensibility plateau predicted the likelihood of food impaction (54). What 311 
is unknown however, is what specific remodeling features have the greatest impact 312 
on the observed differences in esophageal compliance and, more specifically, what 313 
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therapeutic target(s) that are affected during successful treatments. With respect to 314 
motility, the incidence of dysmotility is high in long-term EoE patients (78), In EoE 315 
patients, longitudinal muscle contractility is associated with impaired peristalsis and is 316 
suspected to be associated with dysphagia (34). Submucosal mast cells found in EoE 317 
patients may enhance the contractility of esophageal smooth muscle (1). In mouse 318 
models of EoE, dysmotility of the esophagus similar to that of EoE patients was 319 
observed (40). 320 
 321 
Natural history of EoE and impact of therapeutic interventions 322 
EoE was reported in the early 1990’s but Consensus Recommendations for 323 
diagnosis were first published in 2007 (28). Thus, few studies document long-term 324 
outcomes of this disease. As clinical experiences increase, phenotypic patterns 325 
have been increasingly recognized. For instance, while most children experience 326 
normal growth, some may be found to have malnutrition. To date, no pre- or 327 
malignant potential has been observed but food impactions are common occurrences. 328 
Food impactions develop in upwards of 30 to 45% of patients and are often the 329 
presenting symptom leading to diagnosis (69, 72). Determination of the exact 330 
incidence of stricture depends on how stricture or fibrostenosis is defined. 331 
However, upwards of 67-70% of untreated patients were found to develop 332 
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strictures and in another study, 9% of subjects were found to have an extremely 333 
narrow caliber esophagus (inability to pass a standard adult endoscope) (25, 64, 334 
69). Older age and duration of inflammation are currently considered the most 335 
notable risk factors for having a stricture. For example, in the pediatric population, 336 
fibrostenotic features are reported in up to 16% of the population and impaction in up 337 
to 21% (21, 69). 338 
In an effort to provide optimal outcomes, goals of treatment with diet 339 
elimination of food triggers and topical steroids include reduction of symptoms 340 
and improvement of esophageal eosinophilia. Whether or not these approaches 341 
will alter the natural history of the disease is not certain. However, statistical modeling 342 
of untreated disease suggests an increasing likelihood of developing strictures and 343 
that prolonged use of topical steroid may prevent food impaction (21, 36). In a cohort 344 
study of just over 200 adults with EoE, 9.1% developed food impactions during follow 345 
up periods in which they had stopped topical steroid treatment. In contrast, only 346 
3.5% experienced food impactions when using topical steroid treatment greater than 347 
50% of the time, and even fewer (1.7%) experienced food impaction when taking 348 
treatments >75% of the time (36). While swallowed topical steroids have 349 
demonstrated the ability to impact inflammation, improve symptoms and prevent 350 
complications of EoE when used consistently, adherence to treatment in the 351 
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management of chronic disease remains challenging. Additional options, including 352 
biologics such as anti-IL-5 or IL-13 provide hope for alternative approaches.  353 
 354 
Summary 355 
 In the past two decades since the observation of EoE was first reported, 356 
the clarification of its pathophysiology has advanced. EoE is a chronic disease with a 357 
unique gene expression pattern and an increasingly clear understanding of the 358 
pathophysiology of eosinophil migration, barrier dysfunction and fibrosis has been 359 
elucidated. Therapeutic interventions such as topical steroids may alter the natural 360 
history of EoE even after treatment termination. Based upon a deeper 361 
understanding of the pathologic processes of EoE, we as a field will develop 362 
molecule-targeted therapeutic options with fewer side effects and ultimately better 363 
medical management of patients with EoE. 364 
 365 
  366 
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Figure Legends 367 
Figure 1 368 
Endoscopic findings associated with EoE. A. Normal esophagus- smooth, pink, 369 
lacelike veiled vascular pattern, B. Linear furrows extending longitudinally with loss of 370 
vascular pattern and epithelial edema, C. White exudates representing eosinophilic 371 
pus, D. Longitudinal tear that represents a fragile mucosa. This feature can occur with 372 
the mere passage of the endoscope. 373 
  374 
Figure 2 375 
Histological patterns associated with EoE. A. In the left low power image, infiltration of 376 
eosinophils and epithelial hyperplasia and microabscess (within the circle) can be 377 
seen. B. In the right high power image (from different patient), rete peg elongation 378 
(arrow) and the expansion of intracellular space, so-called spongiosis (within the 379 
circle) is prominent in addition to numerous eosinophilic infiltration.  380 
 381 
  382 
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